Key Takeaways
- Arcadia Biosciences reported Q1 2026 total revenues of $1.1 million, down 8% year-over-year, primarily due to a $193,000 revenue reserve release in Q1 2025 that inflated the prior-year comparison; underlying Zola coconut water unit volumes grew 18% year-over-year.
- Zola coconut water volumes increased 18% and also benefited from a price increase that went into effect at the start of 2026, with SG&A expenses reaching their lowest level in Arcadia's history as a public company.
- Net loss attributable to common stockholders was $4.4 million, or $2.11 per share, compared to net income of $2.6 million, or $1.90 per share, in Q1 2025; the swing was primarily driven by a $2.9 million loss related to the January 2026 warrant inducement offer transaction and the absence of one-time gains recorded in Q1 2025.
- Arcadia raised approximately $2.1 million in gross proceeds from the exercise of previously outstanding preferred investment options during Q1 2026.
- The company is developing a new product expected to reach shelves at many of its largest customers this fall, while continuing to evaluate strategic alternatives and focusing on growing the Zola brand.
Arcadia Biosciences, Inc. (Nasdaq: RKDA) reported first-quarter 2026 financial results with total revenues of $1.1 million and a net loss attributable to common stockholders of $4.4 million. Underlying Zola coconut water unit volumes grew 18% year-over-year and the company reached its lowest SG&A expense level in its public company history, though reported revenue declined 8% and the net result swung to a loss due primarily to a warrant inducement transaction and the absence of one-time gains from Q1 2025.
Arcadia Biosciences Q1 2026 Revenue and Zola Performance
Total revenues were $1.1 million for Q1 2026, down $100,000 or 8% from $1.2 million in Q1 2025. The decline was driven primarily by a $193,000 revenue reserve release recorded in Q1 2025 that does not repeat in 2026, rather than an underlying deterioration in business performance. Zola coconut water unit volumes increased 18% year-over-year, and a price increase implemented at the start of 2026 provided additional revenue support. Cost of revenues increased $18,000 or 3%, reflecting higher product and freight costs on greater Zola sales volume.
“We are very pleased with our performance during the first quarter of 2026. We were able to bring in gross proceeds of approximately $2.1 million from the exercise of previously outstanding preferred investment options, Zola coconut water revenues and volumes increased at a double-digit rate compared to the same quarter last year, and our selling, general, and administrative expenses are at the lowest level in Arcadia's history as a public company,” said T.J. Schaefer, CEO of Arcadia Biosciences.
Operating Expenses and Net Loss
Total operating expenses increased $1.2 million year-over-year to $1.879 million, driven by the absence of two one-time Q1 2025 items: a $750,000 gain on the sale of the company's reduced gluten and oxidative stability patent portfolios and a $1.0 million gain related to the change in fair value of contingent consideration liability. SG&A expenses decreased $559,000 year-over-year, reflecting the absence of M&A fees and lower employee costs in Q1 2026. Net loss attributable to common stockholders was $4.4 million, or $2.11 per share, compared to net income of $2.6 million, or $1.90 per share, in Q1 2025. The $7.0 million swing was primarily attributable to a $2.9 million loss from the January 2026 warrant inducement offer transaction, a $1.5 million other loss, and the absence of the Q1 2025 one-time gains.
Arcadia Biosciences' Outlook: New Product and Strategic Review
Arcadia confirmed it is developing a new product expected to reach the shelves of many of its largest retail customers in the fall of 2026. The company is continuing to evaluate strategic alternatives while maintaining its focus on growing the Zola coconut water brand. Full financial statements are available in the company's Form 8-K and Quarterly Report on Form 10-Q filed with the SEC, accessible through the Investors section of the company's website.
“Going forward, we continue to evaluate strategic alternatives but also remain focused on growing our Zola coconut water brand and are excited about the prospects of launching a new product that we expect to be on the shelves of many of our largest customers this fall,” Schaefer added.
